Hsinchu, Taiwan—based JHL Biotech said it has initiated a phase 1 clinical trial of its denosumab biosimilar candidate JHL 1266, having randomized and treated the first group of patients.

Polaris Group announces closing of US$100 Million fund raising through private placement.

(Reuters) - The U.S. Food and Drug Administration on Thursday approved three generic versions of Swiss drugmaker Novartis AG's top-selling multiple sclerosis (MS) medicine Gilenya.The capital injection turns Blackstone into a long-term strategic investor and promotes the next phase of HEC Pharm’s growth strategy to cement its market position in China

N/A

 Pancreatic cancer is notoriously difficult to treat. One potential opportunity for targeting pancreatic cancer is through its modified amino acid metabolism. Specifically, depriving arginine-dependent tumor cells of arginine can lead to cell death. To achieve this, a polyethylene glycol (PEG)-conjugated arginine deiminase construct (ADI-PEG20) was previously designed and tested as a monotherapy in clinical studies with limited success.

The capital injection turns Blackstone into a long-term strategic investor and promotes the next phase of HEC Pharm’s growth strategy to cement its market position in China

N/A

N/A

SyneuRx International (Taiwan) Corp. today announced that the first five subjects have been randomized for the company’s SND12 Phase IIb/III clinical trial. The trial will study the efficacy and safety of one of its leading investigational therapies, Clozaben^®, for adult subjects with schizophrenia who are refractory to current treatments available.

SyneuRx International (Taiwan) Corp. today announced that the first three subjects have been randomized from the 11 subjects screened into the company’s SND13 Phase IIb/III clinical trial within a short period of time.  The trial will study the efficacy and safety of its leading investigational therapy NaBen^© for adult subjects between 18 and 55 years of age with schizophrenia.